Free shipping on all orders over $ 500
AZD2014 is a novel dual mTORC1 and mTORC2 inhibitor with potential antineoplastic activity. AZD2014 inhibits biomarkers pAKTSer473 and pNDRG1Thr346. AZD2014 has broad antiproliferative activity across multiple tumour cell lines. AZD2014 induces growth inhibition and cell death in breast cancer cell lines, including ER+ cell lines with acquired resistance to hormone therapy. AZD2014 induces tumour growth inhibition against several xenograft models including a human primary explant model of ER+ breast cancer refractory to tamoxifen.
 |
Source | Cell Physiol Biochem (2018). Figure 4. AZD2014 |
| Method | Flow cytometric analysis | |
| Cell Lines | NSCLC cell | |
| Concentrations | - | |
| Incubation Time | 24 h | |
| Results | When mTOR was inhibited in anti-miR-99a-A549 cells by AZD2014, the cells became more sensitive to radiation than control cells and the levels of anti-apoptosis markers were reduced |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Molecular Weight | 462.54 |
| Formula | C25H30N6O3 |
| CAS Number | 1009298-59-2 |
| Purity | >98% |
| Solubility | DMSO 18 mg/mL |
| Storage | at -20°C |
| Related mTOR Products |
|---|
| RMC-5552
The selective mTORC1 complex inhibitor RMC-4529 is a bidentate inhibitor that has a rapamycin-derived, FKBP12-induced heterologous mTOR inhibitor covalently linked to an active-site (orthologous) inhibitor. |
| PQR620
PQR620 is an orally bioavailable and selective brain penetrant inhibitor of mTORC1/2. |
| mTOR inhibitor-3
mTOR inhibitor-3 is a remarkably selective mTOR inhibitor with a Ki of 1.5 nM. mTOR inhibitor-3 suppresses mTORC1 and mTORC2 in cellular and in vivo pharmacokinetic (PK)/pharmacodynamic (PD) experiments. |
| JR-AB2-011
Jr-ab2-011 is a selective mTORC2 inhibitor with an IC50 value of 0.36 μM. Jr-ab2-011 inhibited mTORC2 activity by blocking the Rictor-MTOR complex (Ki: 0.19 μM). Jr-ab2-011 has anti-glioblastoma multiforme (GBM) activity. |
| NV-5138
NV-5138, a leucine analogue, is the first selective, orally active intra-brain mTORC1 agonist in combination with Sestrin2. NV-5138 can be used in biological studies of antidepressants. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.
